the aid library

Remdesivir for COVID-19
recommended

World Health Organization WHO (2022) C_WHO

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Administration of Remdesivir for COVID-19
recommended

World Health Organization WHO (2022) C_WHO

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Advisory for Rational use of Remdesivir for COVID-19 Treatment

Ministry of Health& Family Welfare, Goverment of India (2021) CC

The purpose of this document is to stop to irrational use/ over prescription of this reserve/ experimental/ emergency use authorisation drug Remdesivir. For this reason, Joint Monitoring Group under Chairmanship of DGHS too ... more

Safety and monitoring in patients receiving remdesivir for COVID-19
recommended

World Health Organization WHO (2022) C_WHO

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blocke ... more

WHO Sciene in 5 Episode #37 - Treatment and care at home

World Health Organization WHO (2021) C_WHO

If you have COVID-19 and are caring for someone or yourself at home, what is the treatment protocol? What is WHO’s guidance on Remdesivir and convalescent plasma therapy? How to monitor oxygen at home and what are the red flags when you should cal ... more

A living WHO guideline on drugs for covid-19
recommended

Rochweg, B.; et al. (2021) CC

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379 Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Therapeutics and COVID-19: living guideline (Arabic)
recommended

World Health Organization WHO (2022) C_WHO

3 March 2022 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ... more

Guías de tratamiento farmacológico y manejo de escenarios clínicos de casos de COVID-19

Sociedad Paraguaya de Infectologia (SPI) SPI (2022) C2

Guía de tratamiento farmacológico y manejo deescenarios clínicos de casos de COVID-19 – enero 2022 Guía de tratamiento farmacológico y manejo deLeer más

Ebola case report forms for clinicians. Daily clinical dataset

World Health Organization WHO (2018) C_WHO

These forms are intended only for clinicians and nurses taking care of patients with Ebola virus disease. They provide standardized information that needs to be collected by the clinicians at admission time, every day and at time of discharge.

Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19
recommended

Robert-Koch-Institut RKI (2021) C1

16.7.2021

Declaração sobre Medicamentos para o Tratamento da nova doença de Coronavírus (COVID-19)

Africa Centres for Disease Control and Prevention (Africa CDC); Centro Africano de prevenção e luta contra doenças ; União Africana (2020) C_CDC

O Centro Africano de Prevenção e Luta contra Doenças (CDC-África) está preocupado com a divulgação de informações incorrectas através de meios de comunicação tradicionais e sociais sobre a prevenção e o tratamento de nova doença de coronavírus (COVID-19).

Centros de controle e prevenção de doenças de Àfrica (África CDC) protocolo para o reforço da vigilância de doenças respiratórias agudas e doenças associadas à gripe para o COVID-19 em África

Centros de controle e prevenção de doenças de Àfrica (África CDC); União Africa (2020) C_CDC

Março de 2020 O número de Estados Membros da União Africana a reportarem casos do COVID-19 está a aumentar e existe uma probabilidade de transmissão comunitária. A OMS modificou recentemente a definição de caso suspeito do COVID-19, de modo a incluir infecção respiratória aguda grave ... more

COVID-19 Actualização de Políticas Científicas e de Saúde Pública – (21 de Abril de 2020)

Africa Centres for Disease Control and Prevention (Africa CDC) (2020) CC

Wann könnte die Einleitung einer antiviralen Therapie gerechtfertigt werden?

Robert-Koch-Institut RKI (2020) CC

Erfahrungen im Umgang mit COVID-19-Erkrankten–Hinweise von Klinikern für Kliniker –

Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review

Pan American Health Organisation PAHO (2020) C_WHO

As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I ... more

Notes on the identification, diagnosis and treatment of patients with COVID-19
recommended

Robert-Koch-Institut RKI (2021) C1

16.7.2021

COVID-19 Treatment Guidelines

National Department of Health, South Africa (2022) CC

Updated Treatment Guidelines

Notes for the record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD)
recommended

World Health Organization WHO (2018) C_WHO

Update 27 Agusut 2018